Citations

Clear

626 citation(s) found for "Mehta, SH".

NCOG-03. IMPACT OF THE RATE OF RADIOGRAPHIC RESPONSE (RR) OF BRAIN METASTASES (BM) TO WHOLE BRAIN RADIATION THERAPY (WBRT) ON NEUROCOGNITIVE FUNCTION (NCF) ON NRG-CC001
Devisetty, Kiran , Pugh, Stephanie, Brown, Paul D. , Gondi, Vinai , Solanki, Abhishek A. , Kalapparambath, Tomy, Harmon, Grant, Saripalli, Anjali L. , Chou, Brian, Venkatesulu, Bhanu Prasad , Boike, Thomas , Bovi, Joseph , McGee, Mackenzie, Baschnagel, Andrew, Usuki, Kenneth Y., Kachnic, Lisa A. , Wefel, Jeffrey S. , Kundapur, Vijayananda , Roberge, David , Kruser, Tim J. , Baschnagel, Andrew, Mehta, Minesh P.

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii197-vii197

10.1093/neuonc/noac209.756 Get It

Abstract BACKGROUND The assessment of BM response to WBRT and its impact on NCF in clinical trials has been limited by lack of standardized imaging protocols. NRG-CC001 is a randomized clinical trial requiring pre-specified MRI protocols at baseline and 6-months, providing a uniform dataset to investigate if RR correlates with NCF changes. METHODS NRG-CC001 randomized patients with BM to hippocampal avoidance WBRT (HA-WBRT) or WBRT. NCF was analyzed using 6-month standardized change scores and deterioration, defined using the reliable change index. Chi-square and t-tests were used for pretreatment characteristic comparisons. Inter-rater reliability between central and institutional assessment of RR was assessed with weighted kappa, κ. Linear regression was used to test trends in NCF change scores across types of response and multivariable logistic regression was used to test the association of RR to NCF deterioration. RESULTS 149 and 135 patients were evaluable for RR and NCF assessment, respectively. Pretreatment characteristics were well-balanced, except for post-high school education (70.6% HA-WBRT vs. 52.5% WBRT, p=0.023). Inter-rater reliability between central and institutional assessment of RR was fair (κ=0.36). There was no difference between arms in RR (p=0.41) with overall rates of 14.1% CR, 42.2% PR, 17% SD, and 26.7% PD. Patients with CR had improved 6-month NCF change as measured by HVLT-R Total Recall (p=0.0005), HVLT-R Delayed Recall (p=0.0003), HVLT-R Delayed Recognition (p=0.011), TMT-B (p=0.033), COWA (p=0.016), and Clinical Trial Battery Composite score (p=0.0011). Multivariable analysis demonstrated less deterioration in HVLT-R Delayed Recall for CR (p=0.019) and PR (p=0.0086) vs. SD/PD and HVLT-R Recognition for PR (p=0.031) vs. SD/PD. CONCLUSIONS HA-WBRT and WBRT result in similar RR at 6-months. CR or PR is associated with better NCF preservation. This suggests investigation into treatment escalation for patients with SD/PD may provide further NCF benefit along with HA-WBRT and memantine.Grant support from NCI-UG1CA189867 and U24CA180803.
CTNI-16. NRG-RTOG 9802 OBSERVATION ARM - LONG TERM RESULT
Polley, Mei‐Yin C. , Shaw, Edward , Buckner, Jan C. , Barger, Geoffrey, Coons, Stephen Joel , Ricci, Peter E. , Gilbert, Mark, Brown, Paul D. , Stelzer, K. , Rogers, Leland , Schultz, Christopher J. , Howard, Steven , Fisher, Barbara, Haddock, Michael G. , Won, Minhee , IWAMOTO, FABIO MASSAITI , Coons, Stephen, Suh, John H. , Kim, Michelle H. , Huang, Jiayi , Mehta, Minesh P.

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii73-vii73

10.1093/neuonc/noac209.282 Get It

Abstract BACKGROUND Radiation Therapy Oncology Group 9802 was a phase III trial for patients with centrally confirmed LGG (WHO grade II). Participants ³ 40 years or those with neurosurgeon defined less than gross total resection (GTR) were randomized to radiotherapy (RT) +/- PCV. In a separate cohort, adults age < 40 years with neurosurgeon defined GTR were observed by MRI every 6 months without adjuvant therapy. At last report, outcome for the observation cohort was immature with median follow-up of only 4.4 years. Here, we present mature outcomes for the observation arm. METHODS Eligible adults (as above) were observed by MRI every 6 months. OS and PFS were estimated by Kaplan-Meier method and estimated hazard ratios to characterize the prognostic variables. RESULTS There were 111 eligible patients (median age 30; median KPS = 100). Median follow-up was 16.1 years with 71 (64%) alive at the last follow-up. 79 patients (71%) had progressed with median PFS of 6.9 years. 5, 10, and 15 year-PFS and OS rates were 54%, 39%, 28% and 94%, 77%, and 65%. 1p19q status was codeleted in 32%, IDH1/2 mutant in 78% and MGMT promoter methylated in 39% of tested cases. Multivariate Cox analyses showed that preoperative tumor size ³ 4 cm (HR = 2.43 for PFS, p = 0.001; HR = 2.58 for death, p = 0.016) and residual disease on imaging ³ 1 cm (HR = 2.97 for PFS, P < 0.001; HR = 2.02 for death, p = 0.05) were associated with worse outcomes. Analyses based on molecular results will be presented. CONCLUSION A subset of low-grade gliomas can be observed after the initial resection based on younger age, smaller tumor size, and no residual disease on neuroimaging. This can likely be further refined by prognostic molecular markers. Patients with the most favorable prognostic factors can avoid or delay the acute and long-term side effects of RT and chemotherapy for several years.
A novel through-the-scope helix tack-and-suture device for mucosal defect closure following colorectal endoscopic submucosal dissection: a multicenter study
Farha, Jad , Ramberan, Hemchand, Aihara, Hiroyuki , Zhang, Linda Y. , Mehta, Amit , Hage, Camille , Schlachterman, Alexander , Kumar, Anand , Shinn, Brianna , Canakis, Andrew , Kim, Raymond E., Buscaglia, Jonathan M. , Samarasena, Jason , Chang, Kenneth J. , Friedland, Shai , Qumseya, Bashar , Jawaid, Salmaan , Othman, Mohamed O. , Hasan, Muhammad K. , Khashab, Mouen A., Ngamruengphong, Saowanee , group, ESD-Closure working, Storm, Andrew C , Othman, Mohamed O , Canakis, Andrew , D'Souza, Lionel S. , Storm, Andrew C. , Draganov, Peter V. , Yang, Dennis J. , Khashab, Mouen A. , group, ESD-Closure working

Mayo Clinic

Endoscopy | November 3, 2022 | Volume: 55 | Issue: 06 | Pages: 571-577

10.1055/a-1970-5528 | PMID 36323330 Get It

Background Complete closure of large mucosal defects following colorectal endoscopic submucosal dissection (ESD) with through-the-scope (TTS) clips is oftentimes not possible. We aimed to report our early experience of using a novel TTS suturing system for the closure of large mucosal defects after colorectal ESD. Methods We performed a retrospective multicenter cohort study of consecutive patients who underwent attempted prophylactic defect closure using the TTS suturing system after colorectal ESD. The primary outcome was technical success in achieving complete defect closure, defined as a < 5 mm residual mucosal defect in the closure line using TTS suturing, with or without adjuvant TTS clips. Results 82 patients with a median defect size of 30 (interquartile range 25–40) mm were included. Technical success was achieved in 92.7 % (n = 76): TTS suturing only in 44 patients (53.7 %) and a combination of TTS suturing to approximate the widest segment followed by complete closure with TTS clips in 32 (39.0 %). Incomplete/partial closure, failure of appropriate TTS suture deployment, and the need for over-the-scope salvage closure methods were observed in 7.3 % (n = 6). One intraprocedural bleed, one delayed bleed, and three intraprocedural perforations were observed. There were no adverse events related to placement of the TTS suture. Conclusion The TTS suture system is an effective and safe tool for the closure of large mucosal defects after colorectal ESD and is an alternative when complete closure with TTS clips alone is not possible.
Artificial intelligence-enabled electrocardiographic algorithm for the detection of left ventricular dysfunction in emergency department patients undergoing high-sensitivity cardiac troponin T
Knott, J D, Ola, Oluwabukola Mary , Akula, Ashok , Mehta, Ramila A. , Dworak, Marshall , Lobo, R , Hodge, Dave, Tak, Tahir , Cagin, C, Friedman, Perry , Gulati, R, Jaffe, Allan S. , Sandoval, Yader , Michieli, Laura De , Knott, Jonathan D , Attia, Zachi I. , Ola, O, Friedman, P, Jaffe, Allan S.

Mayo Clinic

European Heart Journal | October 14, 2022 | Volume: 43 | Issue: Supplement_2 | Pages: No page available

10.1093/eurheartj/ehac544.1330 Get It

Abstract Background Artificial intelligence-augmented electrocardiogram (AI-ECG) algorithms have been developed from the standard 12-lead ECG and validated for the recognition of left ventricular systolic dysfunction (LVSD), defined as LV ejection fraction (LVEF)≤35%. Whether AI-ECG facilitates identification of LVSD and is associated with adverse outcomes in emergency department (ED) patients undergoing high-sensitivity cardiac troponin (hs-cTnT) testing is uncertain. Purpose To investigate the diagnostic and prognostic performance of AI-ECG in ED patients undergoing hs-cTnT measurement. Methods Observational US cohort study of ED patients undergoing hs-cTnT measurement. Cases with hs-cTnT increases &gt;sex-specific 99th percentiles were adjudicated following the Fourth Universal Definition of Myocardial Infarction (MI). Post-discharge major adverse cardiac events (MACE) included death, MI, heart failure (HF) hospitalization, stroke or transient ischemic attack, and new onset atrial fibrillation/flutter during 2-years follow-up. The AI-ECG network output, which is a continuous number between 0–1, that provides a probability of LVSD, was obtained for each patient from the first ECG during the index presentation. An AI-ECG threshold of ≥0.256 indicates a positive screen that correlates with a high probability of LVSD. Results Among 1977 patients, 1729 (87%) had a negative AI-ECG screen, while 248 (13%) had a positive AI-ECG screen. Patients with a positive AI-ECG screen were older and had more comorbidities. As compared to patients with hs-cTnT≤99th percentile in whom AI-ECG was positive in 5.8%, those with hs-cTnT&gt;99th percentile had a positive AI-ECG in 22% of cases (p&lt;0.0001). Based on adjudicated diagnoses, the frequency of a positive AI-ECG was 20% in myocardial injury, 38% in type 1 MI, and 20% in type 2 MI. At 2-years follow-up, as compared to patients with a negative AI-ECG, those with a positive AI-ECG had a higher risk for MACE (48% vs. 21%, p&lt;0.0001, adjusted HR 1.39, 95% CI 1.11–1.75) (Figure 1), mainly because of more deaths (43% vs. 30%, p=0.004) and HF hospitalizations (36% vs. 13%, p&lt;0.0001). A positive AI-ECG was associated with a higher risk for MACE (60% vs. 41%, p&lt;0.0001, adjusted HR 1.30, 95% CI 1.02–1.64) in those with hs-cTnT increases &gt;99th percentile, but not in those without hs-cTnT increases. Among patients with an echocardiogram during index presentation or within 30-days (n=452), the diagnostic accuracy of AI-ECG for LVEF ≤35% was 81.4% (95% CI 77.5, 84.9) with a negative predictive value of 96.5% (95% CI 94.0, 98.2). A normal LVEF (&gt;50%) was observed in 87% of those with a negative AI ECG, whereas in those with a positive AI-ECG LVEF was reduced (&lt;50%) in 60%. Conclusions Among ED patients evaluated with hs-cTnT, a positive AI-ECG screen for LVSD identifies patients at high risk of MACE. These findings are largely because of more deaths and HF hospitalizations in those with hs-cTnT increases &gt;sex-specific 99th percentiles. Funding Acknowledgement Type of funding sources: None.
Fetal Alcohol Spectrum Disorder and Iron Homeostasis
Bradley, Regan , Lakpa, Koffi L. , Burd, Michael, Mehta, Sunil , Katušić, Maja , Greenmyer, Jacob R. , Katusic, Maja Z, Bradley, Regan , Katusic, Maja Z.

Mayo Clinic

Nutrients | October 12, 2022 | Volume: 14 | Issue: 20 | Pages: 4223

10.3390/nu14204223 | PMID 36296909 Get It

Prenatal alcohol exposure results in a spectrum of behavioral, cognitive, and morphological abnormalities collectively referred to as fetal alcohol spectrum disorder (FASD). FASD presents with significant phenotypic variability and may be modified by gestational variables such as maternal nutritional status. Iron serves a critical function in the development of and processes within central nervous system (CNS) structures. Gestational iron deficiency alters CNS development and may contribute to neurodevelopmental impairment in FASD. This review explores the relationship between iron deficiency and fetal alcohol spectrum disorder as described in small animal and human studies. Consideration is given to the pathophysiologic mechanisms linking iron homeostasis and prenatal alcohol exposure. Existing data suggest that iron deficiency contributes to the severity of FASD and provide a mechanistic explanation linking these two conditions.
A revision to the United States national ALS registry’s algorithm to improve Case-Ascertainment
Mehta, Paul , Han, Moon, Punjani, Reshma , Brooks, Benjamin Rix , Oskarsson, Björn , Goutman, Stephen A. , Brooks, Benjamin Rix , Oskarsson, Björn , Goutman, Stephen A , Mehta, Paul , Raymond, Jaime S. , Han, Moon, III, Theodore C. Larson , Berry, James D. , Horton, D. Kevin

Mayo Clinic

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration | October 4, 2022 | Volume: 24 | Issue: 3-4 | Pages: 230-236

10.1080/21678421.2022.2121168 | PMID 36194072 Get It

Guidelines for Sexual Health Care for Prostate Cancer Patients: Recommendations of an International Panel
Wittmann, Daniela , McCaughan, Eilís , Faraday, Martha M., Duby, Ashley , Matthew, Andrew, Incrocci, Luca , Nelson, Christian J. , Elliott, Stacy , McLeod, Deborah , Yap, Tet , Higano, Celestia S. , Capellari, Emily, Glodé, Michael, Howell, Doug, Bennett, Nelson , Trost, Landon , Ouma, P Odiyo, Wang, Run , Salter, Carolyn A. , Skolarus, Ted A. , McPhail, John, McPhail, S. Morton, Brandon, Jan, Northouse, Laurel , Paich, Kellie , Pollack, Craig Evan , Shifferd, Jen, Erickson, Kim, Mulhall, John P. , Nelson, Christian J , Mehta, Akanksha , Burnett, Arthur L. “Bud” , Koontz, Bridget F. , Bober, Sharon L. , Capogrosso, Paolo , Loeb, Stacy , Goltz, Heather Honoré , Kirby, Michael G. , McPhail, Susan, Shifferd, Jennifer

Mayo Clinic

The Journal of Sexual Medicine | October 1, 2022 | Volume: 19 | Issue: 11 | Pages: 1655-1669

10.1016/j.jsxm.2022.08.197 | PMID 36192299 Get It

AbstractBackgroundPatients with prostate cancer suffer significant sexual dysfunction after treatment which negatively affects them and their partners psychologically, and strain their relationships.AimWe convened an international panel with the aim of developing guidelines that will inform clinicians, patients and partners about the impact of prostate cancer therapies (PCT) on patients’ and partners’ sexual health, their relationships, and about biopsychosocial rehabilitation in prostate cancer (PC) survivorship.MethodsThe guidelines panel included international expert researchers and clinicians, and a guideline methodologist. A systematic review of the literature, using the Ovid MEDLINE, Scopus, CINAHL, PsychINFO, LGBT Life, and Embase databases was conducted (1995–2022) according to the Cochrane Handbook for Systematic Reviews of Interventions. Study selection was based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Each statement was assigned an evidence strength (A-C) and a recommendation level (strong, moderate, conditional) based on benefit/risk assessment, according to the nomenclature of the American Urological Association (AUA). Data synthesis included meta-analyses of studies deemed of sufficient quality (3), using A Measurement Tool to Assess Systematic Reviews (AMSTAR).OutcomesGuidelines for sexual health care for patients with prostate cancer were developed, based on available evidence and the expertise of the international panel.ResultsThe guidelines account for patients’ cultural, ethnic, and racial diversity. They attend to the unique needs of individuals with diverse sexual orientations and gender identities. The guidelines are based on literature review, a theoretical model of sexual recovery after PCT, and 6 principles that promote clinician-initiated discussion of realistic expectations of sexual outcomes and mitigation of sexual side-effects through biopsychosocial rehabilitation. Forty-seven statements address the psychosexual, relationship, and functional domains in addition to statements on lifestyle modification, assessment, provider education, and systemic challenges to providing sexual health care in PC survivorship.Clinical ImplicationsThe guidelines provide clinicians with a comprehensive approach to sexual health care for patients with prostate cancer.Strengths & LimitationsThe strength of the study is the comprehensive evaluation of existing evidence on sexual dysfunction and rehabilitation in prostate cancer that can, along with available expert knowledge, best undergird clinical practice. Limitation is the variation in the evidence supporting interventions and the lack of research on issues facing patients with prostate cancer in low and middle-income countries.ConclusionThe guidelines document the distressing sexual sequelae of PCT, provide evidence-based recommendations for sexual rehabilitation and outline areas for future research.
Consensus-Based Recommendations on Priority Activities to Address Acute Kidney Injury in Children
Goldstein, Stuart L. , Akcan‐Arikan, Ayse , Alobaidi, Rashid, Bagshaw, Sean M. , Barhight, Matthew , Frazee, Erin N. , Bayrakçı, Benan , Bignall, O. N. Ray , Brophy, Patrick D. , Chanchlani, Rahul , Charlton, Jennifer R. , Conroy, Andrea L. , Deep, Akash , Dolan, Kristin , Fuhrman, Dana Y. , Gorga, Stephen M. , Ulrich, E , Iyengar, Arpana , Krawczeski, Catherine D. , Meigs, Leslie, Menon, Shina , Morgan, Jolyn, Morgan, Catherine , Mottes, Theresa , Neumayr, Tara M. , Ricci, Zaccaria , Selewski, David T. , Sutherland, Scott M. , Symons, Jordan M. , Tavares, Marcelo de Sousa , Vega, Molly Wong , Zappitelli, Michael , Kellum, John A. , Collaborative, Pediatric ADQI, Kellum, John A , Bagshaw, Sean M , Akcan-Arikan, Ayse , Menon, Shina , Askenazi, David J. , Bjornstad, Erica C. , Devarajan, Prasad , Gist, Katja M. , Greenberg, Jason Henry , Hasson, Denise Claire , Jetton, Jennifer G. , Soranno, Danielle E. , Starr, Michelle C. , Stanski, Natalja L. , Ronco, Claudio , Mehta, Ravindra L. , Ostermann, Marlies , Basu, Rajit K. , Collaborative, Pediatric ADQI

Mayo Clinic

JAMA Network Open | September 30, 2022 | Volume: 5 | Issue: 9 | Pages: e2229442

10.1001/jamanetworkopen.2022.29442 | PMID 36178697 Get It

Importance Increasing evidence indicates that acute kidney injury (AKI) occurs frequently in children and young adults and is associated with poor short-term and long-term outcomes. Guidance is required to focus efforts related to expansion of pediatric AKI knowledge. Objective To develop expert-driven pediatric specific recommendations on needed AKI research, education, practice, and advocacy. Evidence Review At the 26th Acute Disease Quality Initiative meeting conducted in November 2021 by 47 multiprofessional international experts in general pediatrics, nephrology, and critical care, the panel focused on 6 areas: (1) epidemiology; (2) diagnostics; (3) fluid overload; (4) kidney support therapies; (5) biology, pharmacology, and nutrition; and (6) education and advocacy. An objective scientific review and distillation of literature through September 2021 was performed of (1) epidemiology, (2) risk assessment and diagnosis, (3) fluid assessment, (4) kidney support and extracorporeal therapies, (5) pathobiology, nutrition, and pharmacology, and (6) education and advocacy. Using an established modified Delphi process based on existing data, workgroups derived consensus statements with recommendations. Findings The meeting developed 12 consensus statements and 29 research recommendations. Principal suggestions were to address gaps of knowledge by including data from varying socioeconomic groups, broadening definition of AKI phenotypes, adjudicating fluid balance by disease severity, integrating biopathology of child growth and development, and partnering with families and communities in AKI advocacy. Conclusions and Relevance Existing evidence across observational study supports further efforts to increase knowledge related to AKI in childhood. Significant gaps of knowledge may be addressed by focused efforts.
Reduced calf pump function and proximal deep vein incompetence are predictors for ipsilateral deep vein thrombosis
Houghton, Damon E. , Ashrani, Aneel A. , Liedl, David , Mehta, Ramila A. , Hodge, David O. , Rooke, Thom W. , Wennberg, Paul W. , McBane, Robert D. , Ashrani, Aneel, Rooke, Thom, Wennberg, Paul, McBane, Robert , Houghton, Damon E , Wysokiński, Waldemar E.

Mayo Clinic

Vascular Medicine | September 30, 2022 | Volume: 28 | Issue: 1 | Pages: 57-58

10.1177/1358863x221124996 | PMID 36178146 Get It

Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT
Jayne, David , Walsh, Michael , Merkel, Peter A. , Peh, Chen Au , Szpirt, Wladimir , Puéchal, Xavier , Fujimoto, Shouichi , Hawley, Carmel M. , Khalidi, Nader , Jones, Rachel , Gregorini, Gina , Harper, Lorraine , Clark, William F. , Smyth, Lucy , Ito‐Ihara, Toshiko , Brezina, Biljana , Mazzetti, Andrea , McAlear, Carol A. , Reidlinger, Donna , Mehta, Samir , Ives, Natalie , Brettell, Elizabeth , Jarrett, Hugh , Wheatley, Keith , Broadhurst, Elizabeth , Casian, Alina , Pusey, Charles D. , Hawley, Carmel , Flossmann, Oliver , Wald, Ron , Girard, Louis , Levin, Adeera , Gregorini, Gina , Harper, Lorraine , Clark, William , Pagnoux, Christian , Specks, Ulrich , Smyth, Lucy , Ito-Ihara, Toshiko , de Zoysa, Janak , Brezina, Biljana , Mazzetti, Andrea , McAlear, Carol A , Reidlinger, Donna , Mehta, Samir , Ives, Natalie , Brettell, Elizabeth A , Jarrett, Hugh , Wheatley, Keith , Broadhurst, Elizabeth , Casian, Alina , Pusey, Charles D , Merkel, Peter A , Khalidi, Nader A , Jayne, David , Pagnoux, Christian , Specks, Ulrich

Mayo Clinic

Health Technology Assessment | September 26, 2022 | Volume: 26 | Issue: 38 | Pages: 1-60

10.3310/pnxb5040 | PMID 36155131 Get It

Background Anti-neutrophil cytoplasm antibody-associated vasculitis is a multisystem, autoimmune disease that causes organ failure and death. Physical removal of pathogenic autoantibodies by plasma exchange is recommended for severe presentations, along with high-dose glucocorticoids, but glucocorticoid toxicity contributes to morbidity and mortality. The lack of a robust evidence base to guide the use of plasma exchange and glucocorticoid dosing contributes to variation in practice and suboptimal outcomes. Objectives We aimed to determine the clinical efficacy of plasma exchange in addition to immunosuppressive therapy and glucocorticoids with respect to death and end-stage renal disease in patients with severe anti-neutrophil cytoplasm antibody-associated vasculitis. We also aimed to determine whether or not a reduced-dose glucocorticoid regimen was non-inferior to a standard-dose regimen with respect to death and end-stage renal disease. Design This was an international, multicentre, open-label, randomised controlled trial. Patients were randomised in a two-by-two factorial design to receive either adjunctive plasma exchange or no plasma exchange, and either a reduced or a standard glucocorticoid dosing regimen. All patients received immunosuppressive induction therapy with cyclophosphamide or rituximab. Setting Ninety-five hospitals in Europe, North America, Australia/New Zealand and Japan participated. Participants Participants were aged ≥ 16 years with a diagnosis of granulomatosis with polyangiitis or microscopic polyangiitis, and either proteinase 3 anti-neutrophil cytoplasm antibody or myeloperoxidase anti-neutrophil cytoplasm antibody positivity, and a glomerular filtration rate of < 50 ml/minute/1.73 m2 or diffuse alveolar haemorrhage attributable to active anti-neutrophil cytoplasm antibody-associated vasculitis. Interventions Participants received seven sessions of plasma exchange within 14 days or no plasma exchange. Oral glucocorticoids commenced with prednisolone 1 mg/kg/day and were reduced over different lengths of time to 5 mg/kg/day, such that cumulative oral glucocorticoid exposure in the first 6 months was 50% lower in patients allocated to the reduced-dose regimen than in those allocated to the standard-dose regimen. All patients received the same glucocorticoid dosing from 6 to 12 months. Subsequent dosing was at the discretion of the treating physician. Primary outcome The primary outcome was a composite of all-cause mortality and end-stage renal disease at a common close-out when the last patient had completed 10 months in the trial. Results The study recruited 704 patients from June 2010 to September 2016. Ninety-nine patients died and 138 developed end-stage renal disease, with the primary end point occurring in 209 out of 704 (29.7%) patients: 100 out of 352 (28%) in the plasma exchange group and 109 out of 352 (31%) in the no plasma exchange group (adjusted hazard ratio 0.86, 95% confidence interval 0.65 to 1.13; p = 0.3). In the per-protocol analysis for the non-inferiority glucocorticoid comparison, the primary end point occurred in 92 out of 330 (28%) patients in the reduced-dose group and 83 out of 325 (26%) patients in the standard-dose group (partial-adjusted risk difference 0.023, 95% confidence interval 0.034 to 0.08; p = 0.5), thus meeting our non-inferiority hypothesis. Serious infections in the first year occurred in 96 out of 353 (27%) patients in the reduced-dose group and in 116 out of 351 (33%) patients in the standard-dose group. The rate of serious infections at 1 year was lower in the reduced-dose group than in the standard-dose group (incidence rate ratio 0.69, 95% confidence interval 0.52 to 0.93; p = 0.016). Conclusions Plasma exchange did not prolong the time to death and/or end-stage renal disease in patients with anti-neutrophil cytoplasm antibody-associated vasculitis with severe renal or pulmonary involvement. A reduced-dose glucocorticoid regimen was non-inferior to a standard-dose regimen and was associated with fewer serious infections. Future work A meta-analysis examining the effects of plasma exchange on kidney outcomes in anti-neutrophil cytoplasm antibody-associated vasculitis is planned. A health-economic analysis of data collected in this study to examine the impact of both plasma exchange and reduced glucocorticoid dosing is planned to address the utility of plasma exchange for reducing early end-stage renal disease rates. Blood and tissue samples collected in the study will be examined to identify predictors of response to plasma exchange in anti-neutrophil cytoplasm in antibody-associated vasculitis. The benefits associated with reduced glucocorticoid dosing will inform future studies of newer therapies to permit further reduction in glucocorticoid exposure. Data from this study will contribute to updated management recommendations for anti-neutrophil cytoplasm antibody-associated vasculitis. Limitations This study had an open-label design which may have permitted observer bias; however, the nature of the end points, end-stage renal disease and death, would have minimised this risk. Despite being, to our knowledge, the largest ever trial in anti-neutrophil cytoplasm antibody-associated vasculitis, there was an insufficient sample size to assess clinically useful benefits on the separate components of the primary end-point: end-stage renal disease and death. Use of a fixed-dose plasma exchange regimen determined by consensus rather than data-driven dose ranging meant that some patients may have been underdosed, thus reducing the therapeutic impact. In particular, no biomarkers have been identified to help determine dosing in a particular patient, although this is one of the goals of the biomarker plan of this study. Trial registration This trial is registered as ISRCTN07757494, EudraCT 2009-013220-24 and Clinicaltrials.gov NCT00987389. Funding This project was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 26, No. 38. See the NIHR Journals Library website for further project information.